Skip to main content
Terug
Watch Compare

Nuo Therapeutics, Inc.

Datakwaliteit: 83%
AURX
OTC Manufacturing Measuring & Analyzing Instruments
€ 1,70
€ 0,00 (0,00%)
Marktkapitalisatie: 82,09 M
Prijs
€ 1,70
Marktkapitalisatie
82,09 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -1,14 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-385,42%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio1,16
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-32,68 | -170,00
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -32,7 -1,5
P/B — 1,6
ROE % — -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 1,70
+76.5%
Koersdoel
€ 3,00
€ 3,00
€ 3,00
€ 3,00
Vooruitzicht
Forward K/W -170,00
Forward WPA -€ 0,01
Omzet Sch. 9,46 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,01
-€ 0,01 – -€ 0,01
 9,46 M 1
FY2026 -€ 0,04
-€ 0,04 – -€ 0,04
 5,75 M 1

Winstverassingen

Laatste 2 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,01 -€ 0,01 0,0%
Q32025 N/A -€ 0,01 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -2,51 M
ROE N/A ROA -152,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1,14 M
ROIC -385,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,16
Interest Coverage N/A Asset Turnover N/A
Working Capital 206.167 Tangible Book Value -419.606
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -32,68 Forward P/E -170,00
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 8,68 Fwd Earnings Yield N/A
FCF Yield -1,39%
Market Cap 82,09 M Enterprise Value 81,58 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45,37%
SBC-Adj. FCF -1,22 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -2,51 M -2,32 M -3,17 M -3,17 M -90.670,0
EPS (Diluted) — — — — -0,03
Gross Profit 2,22 M 1,06 M 482.433,0 93.036,0 0,0
Operating Income -2,52 M -2,46 M -3,17 M -3,32 M -90.670,0
EBITDA — — — — —
R&D Expenses — — — — 0,0
SG&A Expenses 4,73 M 3,52 M 3,65 M 3,41 M —
D&A — — — — 0,0
Interest Expense — — — — 0,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,85 M 1,19 M 1,88 M 3,05 M 1,47 M
Total Liabilities 2,80 M 675.796,0 838.732,0 856.022,0 673.079,0
Shareholders' Equity -956.559,0 513.712,0 1,04 M 2,19 M 792.839,0
Total Debt — — — — 0,0
Cash & Equivalents 548.946,0 283.714,0 928.681,0 2,05 M 1,41 M
Current Assets 1,38 M 841.546,0 1,56 M 2,63 M 1,47 M
Current Liabilities 1,31 M 578.451,0 674.527,0 600.431,0 673.079,0